Elan and Wyeth's Alzheimer's hope fails to impress
This article was originally published in Scrip
Executive Summary
Elanand Wyethhave presented further disappointing results from a closely watched and failed Phase II trial of bapineuzumab, an investigational Alzheimer's disease treatment. Observers had had high hopes for the drug as it is the most developmentally advanced monoclonal antibody directly targeting beta-amyloid, a class of drugs thought to have the potential to reverse patients' neurodegeneration.